SecBot SecBot
Biotech Drug Report Generated Nov 6, 2026

efruxifermin

NVO·NOVO NORDISK A S
NEUTRAL
Drug Impact Rating4/10
Trial phase
Phase 3
Time to market
If Phase 3 trials succeed, a regulatory filing could occur around 2028-2029 for the non-cirrhotic MASH indication (SYNCHRONY Histology data expected H2 2027). The compensated cirrhosis indication (SYNCHRONY Outcomes) has a primary completion date around 2030.
Why 4/10
The next hard catalyst is the SYNCHRONY Real-World Phase 3 safety/tolerability readout expected in Q4 2026 (imminent within weeks), but this is a safety readout, not a pivotal efficacy readout. For Novo Nordisk, a mega-cap company, efruxifermin is one of many pipeline assets, so even a significant readout will not drive a large share-price move.
Actionable Insight NEUTRAL

The next catalyst is the SYNCHRONY Real-World safety readout expected in Q4 2026 (imminent), plus ongoing data presentations at AASLD 2026 (Nov 5-9). Positive safety data would support the Phase 3 program's viability; negative safety signals could delay or derail the program. The pivotal efficacy readout (SYNCHRONY Histology, F2-F3) is not expected until H2 2027, so near-term binary risk for NVO shareholders is limited given the drug is one of many pipeline assets at a mega-cap company.

Price Chart

Loading chart...

Executive Summary

Efruxifermin (AKR-001) is an investigational FGF21 analog being developed for metabolic dysfunction-associated steatohepatitis (MASH), a serious fatty liver disease. Originally developed by Akero Therapeutics, the program was acquired by Novo Nordisk (NVO) for $4.7 billion upfront in a deal that closed December 2025. The drug is currently in Phase 3 clinical trials (the SYNCHRONY program) and has not yet been approved by the FDA, though it has received Breakthrough Therapy Designation. Phase 2b data showed promising fibrosis improvement, including the first-ever evidence of cirrhosis reversal in MASH, though a key trial in compensated cirrhosis (SYMMETRY) missed its primary endpoint at 36 weeks. For Novo Nordisk, a mega-cap company, efruxifermin is a relatively small pipeline asset; the next catalyst is the SYNCHRONY Real-World safety readout expected in Q4 2026.

How It Works

Efruxifermin is an engineered copy of a naturally occurring hormone called FGF21 (fibroblast growth factor 21), which helps regulate metabolism, energy use, and fat processing in the body. It is designed as a once-weekly injection that mimics FGF21's activity to reduce liver fat, inflammation, and scarring (fibrosis) in patients with MASH, a serious fatty liver disease that can lead to cirrhosis and liver failure.

Trial Status

Efruxifermin is in the Phase 3 SYNCHRONY program, which includes three trials: SYNCHRONY Histology (F2-F3 fibrosis, primary efficacy readout expected H2 2027), SYNCHRONY Real-World (safety/tolerability in F1-F4, readout expected Q4 2026), and SYNCHRONY Outcomes (clinical outcomes in F4 cirrhosis, primary completion ~2030). Phase 2b HARMONY (F2-F3) and SYMMETRY (F4) trials have completed with published results.

The Two-Sided Case

▲ Bull Case4
Efruxifermin is the first and only drug to demonstrate reversal of compensated cirrhosis due to MASH in clinical trials, with up to 39% of patients achieving fibrosis improvement at 50 mg in Phase 2b SYMMETRY (HCPLive, 2025).
Phase 2b HARMONY 96-week data showed robust and durable fibrosis improvement, with ~41% of patients on the higher dose achieving at least one-stage fibrosis improvement without worsening of MASH (The Lancet, 2025).
FDA granted Breakthrough Therapy Designation, which can expedite development and review (Akero press release, Dec 2025).
Novo Nordisk paid $4.7B upfront to acquire Akero, signaling strong conviction in efruxifermin's commercial potential and strategic fit with its metabolic disease portfolio (BioSpace, Oct 2025).
▼ Bear Case4
Phase 2b SYMMETRY trial in compensated cirrhosis (F4) missed its primary endpoint at week 36, raising questions about efficacy in advanced disease (NEJM, May 2025).
Treatment discontinuation due to adverse events was higher with efruxifermin (16-18%) vs placebo (2%) in Phase 2 trials, and ~90% of patients developed anti-drug antibodies (The Lancet, 2025).
Resmetirom (Madrigal) is already FDA-approved for MASH with F2-F3 fibrosis, and tirzepatide (Eli Lilly) and other FGF21 analogs (pegozafermin) are in late-stage development, creating a competitive landscape.
For Novo Nordisk (NVO), a mega-cap company, efruxifermin represents a small fraction of overall pipeline value; even positive readouts are unlikely to move NVO shares significantly.

Upcoming Catalysts

  • SYNCHRONY Real-World Phase 3 safety/tolerability readout expected Q4 2026 (imminent)
  • AASLD 2026 (The Liver Meeting, Nov 5-9, 2026) includes post-hoc SYMMETRY analysis and other efruxifermin data presentations
  • SYNCHRONY Histology (F2-F3) primary efficacy data expected H2 2027
  • Potential regulatory filing for accelerated approval if SYNCHRONY Histology meets endpoints

Source Filing

The SecBot filing or press-release report that triggered this drug report:

NOVO NORDISK A S 6-K NVO ·Originating report

Sources · 11

Hover a chip for the title
1 en.wikipedia.org2 akerotx.com3 akerotx.com4 biospace.com5 nejm.org6 akerotx.com7 hcplive.com8 prnewswire.com9 app.biotechtracker.dev10 pharmaphorum.com11 novonordisk-us.com